MedVellum
MedVellum
Back to Library
Sexual Health
Gynaecology
General Practice

Trichomoniasis

High EvidenceUpdated: 2025-12-25

On This Page

Red Flags

  • Pregnancy (Risk of preterm labour)
  • Pelvic Inflammatory Disease (Co-infection risk)
  • HIV Co-infection
  • Treatment Failure
Overview

Trichomoniasis

1. Clinical Overview

Summary

Trichomoniasis ("Trich") is the most common curable sexually transmitted infection (STI) worldwide, caused by the flagellated protozoan parasite Trichomonas vaginalis. It affects approximately 156 million new cases per year globally (WHO). The infection primarily involves the urogenital tract (Vagina, urethra, paraurethral glands) and is transmitted through unprotected sexual intercourse. Women are more commonly symptomatic (50-70%) presenting with frothy, yellow-green, malodorous vaginal discharge, vulval irritation, and dysuria. Men are often asymptomatic carriers. The pathognomonic sign is "strawberry cervix" (colpitis macularis) – punctate red hemorrhages on the cervix. Diagnosis is by NAAT (Gold standard) or wet mount microscopy showing motile flagellated protozoa. Treatment is with metronidazole (400mg BD for 5-7 days or 2g stat). Partner notification and simultaneous treatment are essential. Complications include increased HIV acquisition/transmission risk and adverse pregnancy outcomes (Preterm birth, Low birth weight). Trichomoniasis frequently co-exists with other STIs (Chlamydia, Gonorrhoea) – always screen for co-infections. [1,2,3]

Key Facts

FactValue
DefinitionSTI caused by flagellated protozoan Trichomonas vaginalis
Global Incidence~156 million new cases/year (WHO)
OrganismProtozoan parasite (NOT bacteria or virus)
TransmissionUnprotected sexual intercourse
Symptomatic Women50-70%
Symptomatic Men10-30%
Classic DischargeFrothy, Yellow-green, Malodorous ("fishy")
Pathognomonic SignStrawberry cervix (Colpitis macularis)
Diagnosis Gold StandardNAAT
First-Line TreatmentMetronidazole 400mg BD for 5-7 days
AlternativeMetronidazole 2g stat (Single dose)
Cure RateMore than 90%
Key CautionAvoid alcohol (Disulfiram-like reaction)
HIV RiskIncreases acquisition and transmission
Pregnancy RiskPreterm birth, Low birth weight
Co-infection RateHigh with Chlamydia, Gonorrhoea
Test of CureNot routine; Indicated if persistent symptoms/Pregnancy

Clinical Pearls

"Most Common Curable STI Worldwide": 156 million cases/year. Often underdiagnosed compared to Chlamydia.

"Protozoan, NOT Bacteria": Trichomonas is a flagellated protozoan. It does not respond to penicillin or doxycycline. It needs nitroimidazoles.

"Strawberry Cervix": Pathognomonic sign, But only seen in ~2% with naked eye. Requires colposcopy to see in 50%.

"Frothy, Fishy, Yellow-Green": The classic triad description for exams. If you hear "Frothy", think Trich.

"Men Carry, Women Suffer": Men are often asymptomatic reservoirs who reinfect their treated female partners.

"Metronidazole is Curative": 400mg BD for 5-7 days is the Gold Standard. Single 2g dose is an alternative but has higher failure rates in women.

"No Alcohol Rule": Disulfiram-like (Antabuse) reaction is severe. Counsel every patient to avoid alcohol for 48 hours.

"Partner Treatment Essential": You treat the couple, not the individual. Without partner treatment, reinfection is inevitable.

"Screen for Co-infections": You are never "just" treating Trichomonas. Always check for Chlamydia, Gonorrhoea, Syphilis, and HIV.

"HIV Link": Trichomonas increases HIV acquisition by 1.5-2x due to recruitment of inflammatory cells (CD4 targets) to the mucosa.

"Pregnancy Matters": Associated with preterm labour and low birth weight. Symptomatic pregnant women must be treated.

"NAAT is Gold Standard": Sensitivity >95%. Wet mount is good for immediate diagnosis but misses 40% of cases.

"pH is HIGH": Vaginal pH is almost always >4.5 (usually 5.0-6.0). If pH is normal (Less than 4.5), Trich is unlikely (think Candida).

Diagnostic Criteria Summary

CriteriaFindingSensitivity
SymptomsFrothy discharge, DysuriaLow (Non-specific)
SignsStrawberry CervixVery Low (2%) but Specific
pH> 4.5High (But non-specific, seen in BV)
Wet MountMotile Flagellated Protozoa50-60% (Moderate)
CultureGrowth in liquid medium75-95% (High)
NAATPositive DNA/RNA amplification>95-98% (Gold Standard)

Why This Matters Clinically

Trichomoniasis is more than just a nuisance infection.

  1. Public Health: It is a major driver of the HIV epidemic, facilitating transmission.
  2. Reproductive Health: It causes adverse pregnancy outcomes (preterm birth) and pelvic inflammatory disease (PID).
  3. Quality of Life: The symptoms can be distressing and debilitating for women.
  4. Clinical Skills: Identifying it requires specific skills (microscopy, specific history questions) and excellent communication for partner notification.
  5. Antibiotic Stewardship: Using the right drug (metronidazole) at the right dose prevents resistance.

Historical Context

First described by Alfred Donné in 1836, who observed "animalcules" in purulent discharge. It was long considered a harmless commensal until the mid-20th century when its pathogenicity was confirmed. The introduction of metronidazole in 1960 revolutionised treatment, transforming it from a chronic affliction to a curable condition.

Trichomoniasis is the most common curable STI globally but is frequently underdiagnosed, Especially in asymptomatic men who act as reservoirs. It has significant public health implications due to its association with increased HIV transmission (Inflammation facilitates viral entry), Adverse pregnancy outcomes, And high rates of co-infection with other STIs. Effective management requires treatment of both the index patient AND sexual partners to break the transmission cycle. This condition is commonly examined in OSCE stations focusing on STI history, Discharge assessment, And counselling around alcohol avoidance with metronidazole.


2. Epidemiology

Key Principle

[!NOTE] Trichomoniasis is the most common curable STI worldwide with ~156 million new cases/year. It is underdiagnosed because many cases (Especially in men) are asymptomatic. It has significant public health implications for HIV transmission and pregnancy outcomes.

Incidence & Prevalence

MeasureValueNotes
Global Incidence~156 million/yearWHO estimate (2016)
Global Prevalence~5.3% in women276 million infected
Global Prevalence (Men)~1.4%Often asymptomatic
UK Prevalence1-2%Lower prevalence
US Prevalence2-3% (Women)Higher in certain populations
Prevalence (High-Risk Populations)10-30%Sexual health clinics, Prisons
Prevalence (Antenatal)3-5%Varies by region
Prevalence (HIV-positive Women)10-30%Higher rates

Global Burden by Region

RegionEstimated PrevalenceNotes
Sub-Saharan Africa10-20%Highest global burden
Latin America5-10%Significant burden
Asian-Pacific2-5%Variable
Eastern Europe3-5%Limited data
Western Europe1-3%Lower prevalence
North America2-4%Racial disparities

Demographics - Detailed

FactorDetailsClinical Significance
AgePeak 16-35 yearsSexually active age
Highest Risk Age16-24 yearsScreen actively
SexFemales more symptomaticMales often asymptomatic carriers
Female:Male Ratio (Symptomatic)3:1Women present more often
EthnicityHigher in Black populations (US)May reflect healthcare access
SocioeconomicHigher in lower SESAccess barriers
Sexual BehaviourMultiple partners, Unprotected sexKey risk
Relationship StatusSingle, Multiple partnersHigher risk

Healthcare Utilisation Impact

FactorImpact
UnderdiagnosisMany cases missed (Especially men)
Screening RateLow in many settings
Treatment RateHigh when diagnosed
Reinfection Rate5-15% within 3 months
Partner Treatment RateOften inadequate

Risk Factors - Detailed

High-Risk Groups:

GroupRisk Factor
Sex WorkersOccupational exposure
People Who Inject DrugsRisk behaviours
Incarcerated PopulationsHigh-risk environment
Homeless PopulationsHealthcare access
MSM (Men Who Have Sex With Men)Lower risk (Uncommon in anal sex)
Young Adults (16-24)High prevalence age

Predisposing Factors:

FactorMechanism
Unprotected Sexual IntercoursePrimary transmission route
Multiple Sexual PartnersIncreased exposure
New Sexual PartnerHigher risk
History of STIsMarker of risk behaviour
Concurrent STIsCo-infection common
Non-use of Barrier ContraceptionCondoms protective
Lower Socioeconomic StatusHealthcare access
IncarcerationHigh-risk environment
Sex WorkOccupational risk
Substance UseRisk behaviours
Vaginal DouchingAlters flora

Co-infections - Detailed

Co-infectionPrevalenceClinical Significance
Chlamydia trachomatis10-20%Always screen, Similar treatment timing
Neisseria gonorrhoeae10-15%Always screen, Similar treatment timing
HIVVariableTrichomonas increases HIV acquisition 1.5-2x
Bacterial VaginosisHigh (30-50%)Overlapping flora, Similar pH abnormality
HPVVariableMay increase cervical disease progression
Syphilis1-5%Screen as part of full STI screen
Herpes SimplexVariableMay coexist

Public Health Implications

IssueImpact
HIV Transmission1.5-2x increased risk
Pregnancy OutcomesPreterm birth, Low birth weight
Healthcare CostsSignificant when complications occur
UnderdiagnosisReservoir of infection
Partner Notification ChallengesReinfection common

3. Pathophysiology

Key Principle

[!NOTE] Trichomonas vaginalis is an extracellular, flagellated protozoan parasite. It is an obligate parasite (cannot survive long outside the host). Pathogenesis involves adhesion to the cervicovaginal epithelium, cytotoxicity, and a robust inflammatory response (neutrophil influx) which characterises the clinical discharge and facilitates HIV transmission.

Organism Characteristics - Detailed

FeatureDetailsClinical Relevance
ClassificationProtozoan (Flagellate)Eukaryotic, Anaerobic
MorphologyPear-shaped (Trophozoite)Diagnosable on microscopy
Size10-20µm (Similar to WBC)Can be confused with WBCs if not motile
MotilityJerky, twitching, tumblingDiagnostic feature on wet mount
Flagella4 anterior, 1 posteriorUndulating membrane aids motility
Life CycleNo cyst formOnly exists as trophozoite
ReplicationBinary fissionRapid multiplication
MetabolismAnaerobic (Hydrogenosome)Target for metronidazole
SurvivalFragile outside hostRequires moisture and specific pH

Virulence Factors

FactorFunction
Adhesins (AP65, AP51, AP33)Mediates attachment to vaginal epithelial cells
Cysteine ProteasesDegrades host proteins (IgA, IgG), ECM, and mucin
Cell-Detaching FactorsCauses epithelial cells to detach and die
HemolysinsLyses Red Blood Cells (Source of iron/lipids)
Lipophosphoglycan (LPG)Surface molecule involved in adhesion

Pathophysiology Steps - Detailed

Step 1: Transmission and Colonisation

  • Entry via sexual intercourse (inoculum).
  • Flagella aid movement through vaginal mucus.
  • pH Preference: Thrives in higher pH (5.0-6.0). Normal vaginal acidity (Less than 4.5) is protective.
  • Menstrual blood (pH 7.4) facilitates establishment (hence symptoms often post-menses).

Step 2: Adhesion (Contact-Dependent)

  • Parasite transforms from free-swimming to amoeboid form upon contact.
  • Adhesins bind to laminin and fibronectin on host epithelium.
  • This "kiss of death" contact is required for cytotoxicity.

Step 3: Cytotoxicity and Epithelial Damage

  • Micropinocytosis: Parasite rarely ingests host cells but "nibbles" them.
  • Release of perforin-like proteins and proteases.
  • Induction of host cell apoptosis and necrosis.
  • Disruption of epithelial barrier integrity.

Step 4: The Inflammatory Response (The "Purulent" Phase)

  • Host epithelial cells release chemokines (IL-8).
  • Massive influx of Neutrophils (PMNs) into the vaginal lumen.
  • Discharge: The frothy, yellow-green discharge is largely composed of neutrophils and dead epithelial cells.
  • Free Radical Release: Neutrophils release ROS, causing further tissue irritation.

Step 5: Impact on Vaginal Microbiome

  • T. vaginalis correlates with loss of healthy Lactobacillus.
  • Synergistic relationship with BV-associated bacteria (Gardnerella, Mycoplasma).
  • Both thrive in anaerobic, high pH environment.
  • The high pH neutralises the protective effect of lactic acid.

Step 6: "Strawberry Cervix" Formation

  • Colpitis Macularis: Local dilation of capillaries and punctate hemorrhages.
  • Caused by high local concentration of organisms and inflammatory mediators.
  • Gives the mottled red appearance.

Immune Evasion Mechanisms

MechanismHow it Works
Antigenic VariationChanges surface proteins to evade antibodies
Protease SecretionDegrades host immunoglobulins (IgA, IgG)
Complement EvasionResists lysis by alternate complement pathway
Phagocytosis EscapeToo large to be easily phagocytosed by neutrophils
Molecular MimicrySurface proteins mimic host proteins

The HIV Connection (Crucial Mechanism)

Trichomoniasis increases HIV transmission risk by 2-fold via:

  1. Epithelial Breach: Micro-ulcerations provide entry portal for virus.
  2. Target Cell Recruitment: Inflammation recruits CD4+ T-cells and Macrophages (HIV targets) to the genital tract.
  3. Viral Shedding: Increase HIV RNA shedding in co-infected individuals.
  4. Flora Disruption: Loss of protective H2O2-producing lactobacilli.

Pathophysiology Diagram

Trichomoniasis Pathophysiology

Pathophysiology Diagram

Trichomoniasis Management Algorithm


4. Clinical Presentation

Key Principle

[!NOTE] Trichomoniasis Presentation:

  • Women: 50-70% symptomatic. Classic triad: Frothy yellow-green discharge, Vulval irritation, Dysuria.
  • Men: 70-90% asymptomatic. Key reservoir for transmission.
  • Pathognomonic: Strawberry cervix (Colpitis macularis) - Specific but insensitive.

Incubation and Course

FeatureDetails
Incubation Period4-28 days (Range 2 days to 3 months)
OnsetCan be sudden or insidious
CoursePersistent if untreated (Can last years)
Symptom FluctuationSymptoms may worsen during menstruation (Higher pH)
Asymptomatic IntervalCan be asymptomatic for years before symptoms appear

Presentation by Sex - Detailed

Women (Symptomatic in 50-70%):

SymptomDescriptionFrequencyClinical Note
Vaginal DischargeProfuse, Frothy, Yellow-green, Malodorous ("fishy")50-75%Can be confused with BV
Vulval IrritationItching (Pruritus), Soreness, Burning30-50%Can be severe
DysuriaPain on urination (External due to vulvitis)30%"Stinging" sensation
DyspareuniaSuperficial pain during intercourse20-30%Due to inflammation
Lower Abdominal PainMild, Dull ache10-20%If severe, exclude PID
Post-Coital BleedingSpotting after sexLess commonDue to cervicitis

Men (Asymptomatic in 70-90%):

SymptomDescriptionFrequencyClinical Note
AsymptomaticNo symptoms70-90%"Silent carrier"
Urethral DischargeScant, Clear/White, Mucoid5-15%Often morning only
Urethral IrritationItching inside penis, Mild burning5-15%"Tickling" sensation
DysuriaMild pain on urination5-10%Need to exclude Chlamydia/Gonorrhoea
ProstatitisPerineal pain, Ejaculatory painLess than 5%Chronic reservoir
BalanitisInflammation of glansRareIn uncircumcised men

Differential Diagnosis - Vaginal Discharge

FeatureTrichomoniasisBacterial Vaginosis (BV)Vulvovaginal Candidiasis (Thrush)Normal Discharge
Primary ComplaintDischarge + IrritationMalodorous DischargeItching +++None
Discharge ColourYellow-greenGrey-whiteWhiteClear/White
Discharge ConsistencyFrothy, PurulentThin, Homogeneous, WateryThick, Curdy ("Cottage Cheese")Mucoid, Variable
OdourFishy (Offensive)Fishy (Amine)None / YeastyNon-offensive
Vaginal pHMore than 4.5 (High)More than 4.5 (High)Less than 4.5 (Normal)Less than 4.5
InflammationPresent (Erythema)Absent (Non-inflammatory)Present (Erythema, Fissures)Absent
Whiff TestPositivePositiveNegativeNegative
MicroscopyMotile protozoaClue cellsHyphae/SporesEpithelial cells

Red Flags requiring Urgent/Specialist Assessment

Red FlagClinical ReasoningImmediate Action
PregnancyRisk of Preterm Labour (PTL) and Premature Rupture of Membranes (PROM).Urgent Treatment. Do not delay. Avoid high-dose stat regimen in 1st trimester if possible.
Pelvic Pain / Deep DyspareuniaSuggests ascending infection (PID). T. vaginalis can facilitate bacterial ascent.PID Protocol. Cover for Gonorrhoea, Chlamydia, Anaerobes. Add Metronidazole.
Systemic Symptoms (Fever, Malaise)Complicated infection (PID, Tubo-ovarian abscess) or Disseminated Gonorrhoea.Admit or Urgent GUM referral. septic screen.
Cervical Motion TendernessHallway sign of PID ("Chandelier Sign").Treat for PID immediately.
HIV PositiveIncreased viral shedding; Higher risk of treatment failure.Treat promptly. Ensure 7-day course (Single dose has higher failure rate in HIV).
Pre-pubertal ChildSafeguarding Red Flag. Trichomonas is almost exclusively sexually transmitted.Safeguarding Referral. Paediatric assessment. Do not simply treat.
Recurrent InfectionReinfection (partner) or Resistance.Detailed sexual history. Partner check. Culture for resistance.
Male with Dysuria/DischargeRare. Symptoms in men usually mean high organism load or co-infection.Screen for all STIs. Check for epididymo-orchitis.

[!CAUTION] Safeguarding Alert: Diagnosis of Trichomonas vaginalis in a child is a definitive marker of sexual abuse until proven otherwise, as it is not commensal and does not survive in the environment.

Assessment of Complications (Algorithm)

FindingSuggestsAction
Cervical Motion TendernessPIDTreat for PID (Ceftriaxone + Doxy + Metro)
Urethral Discharge (Men)UrethritisGram stain, NAAT for CT/NG/MG/TV
Testicular PainEpididymo-orchitisScreen and treat
Joint Pain / RashReactive Arthritis (Reiters)Rare complication of STIs
Abdominal Pain (RUQ)Fitz-Hugh-Curtis SyndromeRare peri-hepatitis (usually Chlamydia, possible with others)

5. Clinical Examination

Key Principle

[!NOTE] Detailed examination is crucial not just for diagnosis, but for assessing complications (like PID) and co-infections (like Herpes or Syphilis).
Always examine:
> 1. Abdomen (Tenderness) > 2. External Genitalia (Ulcers, Dermatitis) > 3. Speculum (Discharge, Cervicitis) > 4. Bimanual (Tenderness - PID check)

Examination Protocol: Women

1. Abdominal Examination:

  • Palpate lower abdomen.
  • Tenderness in iliac fossae suggests Pelvic Inflammatory Disease (PID) or other pathology.

2. External Genital Inspection:

  • Vulvitis: Look for erythema and oedema of the labia and introitus.
  • Dermatitis: Excoriations from scratching (itch).
  • Discharge: May be visible at the introitus (yellow/green).
  • Other STIs: Check for Herpes ulcers, Syphilis chancres, Warts.

3. Speculum Examination (Crucial Step):

  • Discharge: Look for pooling in the posterior fornix.
    • Classic: Frothy, Yellow-green, Bubbles visible.
    • Note: Mucopurulent discharge from the OS suggests Gonorrhoea/Chlamydia.
  • Vaginal Walls: Erythematous, "Angry" appearance.
  • Cervix:
    • "Strawberry Cervix" (Colpitis Macularis): Punctate petechial hemorrhages.
    • Friability: Bleeds easily on contact (swabbing).
  • pH Testing: Touch indicator paper to lateral vaginal wall.

4. Bimanual Examination:

  • Goal: Exclude PID / Upper Genital Tract Infection.
  • Cervical Motion Tenderness (CMT): "Chandelier sign" - pain on moving cervix.
  • Adnexal Tenderness: Pain in ovarian regions.
  • Uterine Tenderness: Pain on compressing uterus.
  • If any of these are positive, treat for PID immediately.

Examination Protocol: Men

1. Inspection:

  • Urethral Meatus: Check for discharge (may need to "milk" the urethra).
  • Glans/Prepuce: Check for Balanitis (inflammation), Ulcers, Warts.

2. Palpation:

  • Testicles: Check for tenderness/swelling (Epididymo-orchitis).
  • Epididymis: Tenderness suggests ascending infection.

3. Digital Rectal Exam (DRE):

  • Only if prostatitis suspected (Perineal pain, dysuria +++).
  • Boggy, tender prostate.

Documentation Checklist (Medico-legal)

ItemStatusExample Entry
ConsentRequired"Verbal consent obtained for examination"
ChaperoneMandatory"Chaperoned by Nurse X"
AbdomenFindings"Soft, non-tender"
ExternalFindings"Vulva erythematous, no ulcers"
SpeculumFindings"Cervix visualised, strawberry appearance, frothy green discharge"
BimanualFindings"No cervical motion tenderness, no adnexal masses"
SamplesSwabs taken"HVS (wet mount) + NAAT taken"

"Use of the Speculum" - Clinical Tips

[!TIP] Optimising the Exam: > 1. Warm the speculum: Cold metal causes muscle spasm. > 2. Lubrication: Use water or minimal water-soluble lube (excess lube can interfere with slides/swabs). > 3. Angle: Insert at 45 degrees, then rotate to horizontal. > 4. Visualize: Ensure you can see the cervix fully to rule out "Strawberry" spots. > 5. Swab Order:

  • 1st: Charcoal Swab (Bacteria/Candida) - If needed
  • 2nd: NAAT (DNA) - Or first if sole test
  • 3rd: pH/Wet Mount - Last

Strawberry Cervix - Detailed

AspectDetails
DescriptionPunctate red/hemorrhagic spots on cervix
PathologyDilated capillaries + micro-hemorrhages
PrevalenceOnly 2-5% visible to naked eye
ColposcopyVisible in >50% if using colposcope (magnification)
Diagnostic ValueHighly specific (Pathognomonic) but low sensitivity
DifferentialAtrophic vaginitis (post-menopausal) can look similar

Vaginal pH Interpretation Guide

pH ValueInterpretationPotential Diagnosis
Less than 4.5Normal (Acidic)Physiological, Candida
4.5 - 5.0Mildly ElevatedBV, Trichomoniasis
5.0 - 6.0Moderately ElevatedTrichomoniasis (Often higher than BV)
More than 6.0Highly ElevatedTrichomoniasis, Atrophic Vaginitis, DIV
More than 7.0Neutral/AlkalineMenses, Semen, Amniotic Fluid

6. Investigations

Key Principle

[!IMPORTANT] Diagnostic Approach: > 1. NAAT (Nucleic Acid Amplification Test) is the Gold Standard (Sensitivity >95%). > 2. Wet Mount Microscopy provides immediate point-of-care diagnosis but has low sensitivity (50-60%) - A negative result does NOT exclude Trichomoniasis. > 3. Vaginal pH > 4.5 supports the diagnosis (but is non-specific).

Diagnostic Tests Comparison

TestSensitivitySpecificityTurnaroundAdvantagesDisadvantages
NAAT (PCR)95-100%98-100%1-3 daysGold standard, Highly sensitive, Self-swabDelayed result
Wet Mount50-60%VariableImmediatePoint-of-care diagnosis, Motility seenLow sensitivity, Operator dependent
Rapid Antigen80-90%95%15 minsFaster than NAATLess sensitive than NAAT
Culture75-85%100%3-7 daysCan test for resistanceSlow, Labour intensive
pH TestingLowLowImmediateSupportive evidenceNon-specific (High in BV too)

NAAT Testing Strategy (Gold Standard)

Sample Sites:

PatientSample TypeSensitivity
WomenVulvovaginal Swab (Self-taken)98-100% (Best)
WomenEndocervical Swab (Clinician)95-98%
WomenFirst Void Urine90-95% (Less preferred)
MenFirst Void Urine95-98% (Best)
MenUrethral SwabHigh

Protocol:

  • Often included in "Triple Screen" panels (Chlamydia + Gonorrhoea + Trichomonas).
  • Can use same swab technology as for CT/NG (e.g. Aptima).
  • Window Period: Can detect reliable DNA 4-7 days after exposure.

Wet Mount Microscopy (Point-of-Care)

Procedure:

  1. Take High Vaginal Swab (HVS) from posterior fornix.
  2. Place directly into tube of normal saline (0.9%).
  3. Place drop on slide with cover slip.
  4. Examine immediately (within 10-15 mins) under phase-contrast (x400).

Findings:

  • Trichomonads: Pear-shaped, slightly larger than WBCs.
  • Motility: Characteristic jerky / twitching / tumbling motion.
  • WBCs: Usually abundant (>10 per HPF).
  • Clue Cells: May be present (Concurrent BV).

[!WARNING] Negative Microscopy: If wet mount is negative but symptoms persist or suspicion is high, you MUST send a NAAT. Do not rely solely on microscopy.

Vaginal pH Testing

Procedure:

  • Touch pH paper to vaginal wall (mid-vagina).
  • Avoid cervical mucus (pH 7.0) or lubricant.

Interpretation:

  • Normal: pH Less than 4.5
  • Trichomoniasis: pH > 4.5 (Often 5.0-6.0)
  • Bacterial Vaginosis: pH > 4.5
  • Candida: pH Less than 4.5 (Normal)

Additional Investigations and Screening

Full STI Screen (Recommended for all):

TestRationale
Chlamydia NAAT10-20% co-infection rate
Gonorrhoea NAAT10-15% co-infection rate
HIV SerologyTrichomoniasis facilitates transmission
Syphilis SerologyRoutine screen
Hepatitis B/CBased on risk factors

Speculum Examination Checklist:

  1. Inspect Vulva: Dermatitis, discharge.
  2. Insert Speculum: Note discharge characteristics.
  3. Inspect Cervix: Look for "Strawberry" signs (Colpitis macularis).
  4. Take Swabs: HVS (pH/Wet mount) + NAAT.
  5. Bimanual: Check for tenderness (PID).

Why Culture is Rarely Used Now

  • InPouch TV System was historic gold standard.
  • Requires incubation for up to 7 days.
  • Lower sensitivity than modern NAAT.
  • Now primarily used for Resistance Testing (sending isolates to reference labs).

7. Management

Key Principle

[!IMPORTANT] Metronidazole is curative (More than 90% cure rate) Partner notification and treatment essential Avoid alcohol during treatment (Disulfiram reaction)

Management Algorithm

Trichomoniasis Management Algorithm

First-Line Treatment - Detailed

RegimenDoseDurationCure RateNotes
Metronidazole400mg BD5-7 daysMore than 95%First-line, Preferred
Metronidazole2g statSingle dose85-90%Alternative (Higher side effects)

7-Day vs Single Dose Comparison:

Factor7-Day CourseSingle Dose
Cure RateMore than 95%85-90%
AdherenceRequires memoryBetter compliance
Side EffectsLess nauseaMore nausea
Partner TreatedBoth can take courseBoth take stat
Preferred InPregnancyNon-pregnant, No follow-up

Second-Line Treatment - Detailed

RegimenDoseDurationIndicationNotes
Tinidazole2g statSingleMetronidazole failure/intoleranceBetter GI tolerance
High-Dose Metronidazole400mg TDS7-14 daysResistant infectionIf low-level resistance
Tinidazole2g OD14 daysResistant infectionHigh-level resistance
Combined Tinidazole + Intravaginal MetronidazoleVariable14 daysRefractory casesSpecialist

Metronidazole Pharmacokinetics & Interactions

ParameterDetailsClinical Implication
Bioavailability>90% (Oral)IV rarely needed
Half-life8 hoursBD dosing or Stat dose works
MetabolismHepatic (CYP450)Caution in severe liver disease
ExcretionRenal (60-80%)Dark urine common
Protein BindingLess than 20%Good tissue penetration

Key Drug Interactions:

DrugInteraction TypeConsequenceManagement
AlcoholInhibition of Aldehyde DehydrogenaseDisulfiram reaction (Vomiting, Flushing)AVOID during + 48h after
WarfarinCYP2C9 InhibitionIncreased INR (Bleeding risk)Monitor INR closely; Reduce Warfarin
LithiumReduced Renal ClearanceLithium ToxicityMonitor Lithium levels
PhenytoinMetabolism InhibitionPhenytoin ToxicityMonitor levels
CyclosporinEnzyme InhibitionIncreased CyclosporinMonitor levels

Prescribing in Special Populations (Detailed)

1. Pregnancy:

  • First Trimester: Metronidazole 400mg BD for 7 days is safe. Avoid high-dose stat regimens if possible (theoretical risk, though evidence supports safety).
  • Second/Third Trimester: Metronidazole 400mg BD for 7 days.
  • Preterm Risk: Symptomatic infection must be treated to reduce preterm birth risk.
  • Asymptomatic Screening: Not routinely recommended.

2. Breastfeeding:

  • Metronidazole is excreted in breast milk.
  • Standard Advice: Safe to use. Large doses (2g stat) may cause bitter taste in milk.
  • Strategy: Can withhold breastfeeding for 12-24 hours after 2g stat dose if concerned, or use 400mg BD regimen (levels lower).
  • British National Formulary (BNF): "Amount too small to be harmful."

3. Renal Impairment:

  • CKD 1-3 (eGFR > 30): No dose adjustment needed.
  • CKD 4-5 (eGFR Less than 30): No dose adjustment usually needed for short course, but monitor for metabolites.
  • Dialysis: Metronidazole is removed by dialysis. Administer dose after dialysis session.

4. Hepatic Impairment:

  • Mild/Moderate: No adjustment.
  • Severe (Child-Pugh C): Reduce dose by 50% or increase interval (e.g. 400mg OD), as metabolism is slowed.

5. Metronidazole Allergy:

  • True allergy (anaphylaxis) is rare but challenging.
  • Alternatives:
    • Tinidazole: Often cross-reactivity exists (contraindicated).
    • Desensitisation: Oral desensitisation protocols available in specialist centres.
    • Non-Nitroimidazole agents: Paromomycin (intravaginal) or high-dose Clotrimazole have very low cure rates (Less than 50%) and are not recommended unless absolute necessity.
    • Referral: All true allergy cases require GUM Specialist management.

Metronidazole Counselling - Detailed

Essential Counselling Points:

PointWhat to Say
Complete Course"Take all the tablets even if you feel better"
Timing"Take with food to reduce stomach upset"
No Alcohol"No alcohol for 48 hours after finishing"
Alcohol Reaction"Alcohol will make you very sick (Vomiting, Flushing, Headache)"
Side Effects"You may notice nausea, Metallic taste – These are normal"
Partner Treatment"Your partner must be treated too"
No Sex"Avoid sex until both have finished treatment + 7 days"
Follow-Up"Come back if symptoms don't improve"

Sample Counselling Script (OSCE):

"I'm prescribing you an antibiotic called Metronidazole. You'll take one tablet twice a day for 7 days. It's very important that you take all the tablets, Even if you feel better. There's one very important thing – You must NOT drink any alcohol while taking these tablets, And for 48 hours after finishing. If you do, You'll become very unwell with severe vomiting, Flushing, And headaches. Common side effects include nausea and a metallic taste, Which are normal. Your partner must be treated at the same time, Even if they have no symptoms. You should both avoid sex until 7 days after you've both finished treatment. Does that all make sense? Any questions?"

Partner Notification - Detailed

AspectDetails
EssentialPartner treatment mandatory to prevent reinfection
Method: Patient ReferralPatient tells partner to attend
Method: Provider ReferralHealthcare contacts partner (With consent)
Method: Contact SlipPatient gives slip to partner
Epidemiological TreatmentTreat partner without testing
Lookback PeriodCurrent partner(s)
Avoid SexUntil both completed treatment + 7 days

Partner Notification Counselling:

PointWhat to Say
Why"Your partner needs treatment to stop you getting reinfected"
Even if No Symptoms"Many people have no symptoms but can still pass it on"
How to Tell Them"Would you prefer to tell them, Or would you like us to contact them?"
Contact Slip"Give them this slip – They can attend any sexual health clinic"
Timing"Please tell them as soon as possible"

Test of Cure

IndicationWhenMethod
Persistent Symptoms2 weeks after treatmentNAAT
Pregnancy1 month after treatmentNAAT
High Reinfection Risk3 monthsNAAT
Routine (Asymptomatic)Not required-
Treatment Failure Suspected2 weeksNAAT + Culture

Management of Treatment Failure (Step-by-Step)

If symptoms persist or test remains positive:

Step 1: Check Compliance & Sexual History (The Basics)

  • Adherence: Did they take the pills? (Did they vomit?)
  • Timing: Did they complete the course?
  • Alcohol: Did they stop alcohol (avoiding vodka-vomiting)?
  • Re-exposure: Did they have sex? Was partner treated? (Most common cause)

Step 2: Reinfection vs Relapse

  • Reinfection: Most likely (>90%). New exposure or untreated partner.
    • Action: Retreat with standard course (Metronidazole 400mg BD x 7 days).
    • Partner: Ensure partner is treated (Supervised therapy if needed).
  • Relapse: Persistence despite adherence and no re-exposure.
    • Action: Suspect resistance or poor absorption.

Step 3: Empiric Second-Line (If compliance confirmed)

  • Regimen: Metronidazole 400mg TDS for 7 days (UK) or Tinidazole 2g single dose.
  • Alternative: Tinidazole 500mg QDS for 1 week (High dose).
  • Note: High dose metronidazole/tinidazole has more side effects (nausea, neurotoxicity).

Step 4: Refractory / Resistant Cases

  • Definition: Failure of nitroimidazole treatment after excluding reinfection/non-compliance.
  • Action:
    1. Culture: Swab for Culture and Sensitivity (Reference Lab).
    2. Specialist Management: Referral to GUM consultant.
    3. High Dose Tinidazole: 1g BD or TDS for 14 days (Specialist only).
    4. FemCure Trial Regimens: Dequalinium Chloride (10mg PV OD x 6 days) – Shows promise.
    5. Paromomycin: Intravaginal cream (Poor efficacy, side effects).
    6. Boric Acid: Low cure rate, salvage only.

[!WARNING] Metronidazole Resistance:

  • Rare (Less than 5%) but increasing worldwide.
  • Mechanisms involve reduced nitroreductase activity in the hydrogenosome.
  • Do not keep repeating the same failing dose. Escalate to specialist.

Alternative / Natural Remedies (Facts and Myths)

Patients frequently ask about non-antibiotic treatments. It is important to be clear:

"Remedy"EfficacyClinical Advice
Vaginal DouchingHarmfulIncreases risk of PID, BV, and ectopic pregnancy. Pushes bacteria up. Do not use.
Tea Tree OilMinimal/UnknownCan cause severe chemical dermatitis/burns. Not recommended.
ProbioticsSupportive onlyGood for restoring flora post-antibiotic (Lactobacillus), but does not cure Trichomoniasis.
Garlic (PV)NoneNo evidence. Can cause chemical burns to mucosa.
Cranberry JuiceNoneUseful for UTIs (anti-adhesion), useless for vaginal trichomoniasis.
Boric AcidLowSometimes used as salvage for resistant cases, but cure rates are low (Less than 40%).
YoghurtNoneSoothing for Candida, useless for Trichomonas.

[!TIP] Counselling Tip: "This is a parasite that 'swims'. Flushing it with water or using herbal remedies won't kill it. You need the specific antibiotic that stops its engine (hydrogenosome) working."

Follow-Up Strategy

IndicationActionTimeframe
Asymptomatic after TreatmentNo follow-up needed-
Persistent SymptomsRe-test (NAAT/Culture)2 weeks post-treatment
PregnancyTest of Cure (TOC)1 month post-treatment
High Risk of ReinfectionRescreen3 months
Vomited MedicationRepeat doseImmediate
FactorDetails
PrevalenceLess than 5% in UK
IncreasingEmerging concern
TestingSpecialised centres
ManagementHigher doses, Longer courses, Tinidazole

OSCE Station: Trichomoniasis Counselling

Expected Competencies:

TaskWhat to Do
Explain Diagnosis"You have an infection called Trichomoniasis"
Cause"It's caused by a tiny parasite passed on during sex"
Treatment"Antibiotic tablets for 7 days"
Alcohol Warning"Absolutely no alcohol for 48 hours after finishing"
Partner Treatment"Your partner must be treated too"
Avoid Sex"Both avoid sex until 7 days after treatment finished"
Follow-Up"Come back if symptoms don't go"
Check Understanding"Can I check you understand?"

8. Complications

Overview

CategoryComplicationsFrequency
ReproductivePID, InfertilityRare but possible
PregnancyPreterm birth, PROM, Low birth weightSignificant (1.4x risk)
InfectiousHIV Acquisition, HIV Transmission1.5-2x risk
MaleProstatitis, Epididymitis, UrethritisUncommon
PsychologicalAnxiety, Relationship breakdownCommon

Pregnancy Complications - Detailed Mechanisms

Preterm Birth and Low Birth Weight:

  • Risk: 1.4-1.8x increased risk of preterm delivery (Less than 37 weeks).
  • Mechanism:
    1. T. vaginalis produces proteases that degrade the chorioamniotic membrane.
    2. Induces local inflammation (IL-8, Prostaglandins).
    3. Prostaglandins trigger uterine contractions.
    4. Weakening of membranes leads to PROM (Premature Rupture of Membranes).

Implication for Management:

  • Symptomatic pregnant women MUST be treated.
  • Screening asymptomatic pregnant women is controversial (some studies suggested treatment might increase PTB, but recent guidelines suggest treating).

The HIV Synergy (Public Health Critical)

1. Increased Acquisition (Getting HIV):

  • T. vaginalis causes microscopic ulcerations in the epithelium.
  • It recruits CD4+ T-cells (HIV targets) to the vaginal/cervical mucosa.
  • Result: An HIV-negative person with Trichomoniasis is 1.5-2 times more likely to acquire HIV if exposed.

2. Increased Transmission (Passing HIV):

  • In HIV-positive individuals, Trichomoniasis increases genital viral shedding.
  • Result: An HIV-positive person with Trichomoniasis is more infectious to their partners.

[!IMPORTANT] Conclusion: Effective control of Trichomoniasis is a crucial HIV prevention strategy.

Pelvic Inflammatory Disease (PID)

  • T. vaginalis is an independent risk factor for PID.
  • Can transport bacteria into the upper genital tract ("Trojan Horse" effect).
  • Presentation: Pelvic pain, deep dyspareunia.
  • Management: If PID suspected, treat for PID (covering GC/CT/Anaerobes) + add Metronidazole for TV.

Male Complications (Under-recognised)

ConditionMechanism
NGU (Non-Gonococcal Urethritis)10-20% of NGU cases are caused by TV
Chronic ProstatitisParasite can colonise the prostate gland
EpididymitisAscending infection
InfertilityReduced sperm motility, agglutination

9. Prognosis & Outcomes

Treatment Efficacy

RegimenCure RateRelapse Rate
7-Day Metronidazole95-98%Low
Single Dose Metronidazole85-90%Moderate (Higher failure)
Tinidazole90-95%Low
No Treatment20-30% spontaneous resolution70% persistence (Chronic)

Prognostic Factors

Good Prognosis Indicators:

  • Adherence to 7-day course.
  • Partner simultaneously treated.
  • Sexual abstinence during treatment.
  • No co-infections.

Poor Prognosis Indicators:

  • Co-infection (Bacterial Vaginosis).
  • Untreated partner (Reinfection is #1 cause of "failure").
  • HIV infection (May require longer course).
  • Non-adherence (Alcohol use, Nausea).

Reinfection vs Resistance

Reinfection (Common):

  • Occurs in ~17% of women within 3 months.
  • Usually due to resumption of sex with untreated partner.
  • Management: Retreatment + Strict partner notification.

Resistance (Rare):

  • Occurs in Less than 5% of cases.
  • Mechanism: Altered metabolic pathways (reduced nitroreductase activity in hydrogenosome).
  • Classification:
    • Low-level: Responds to higher dose Metronidazole.
    • High-level: Requires Tinidazole or specialist regimens.

Long-Term Sequelae

  • No protective immunity: Patients can get Trichomoniasis multiple times.
  • No chronic carrier state (after cure): Once cured, the parasite is gone.
  • Fertility: Usually preserved if no PID.

10. Evidence & Guidelines

Key Guidelines Summary

GuidelineOrganisationYearKey Recommendations
BASHH United Kingdom National GuidelineBASHH (UK)20217-day Metronidazole 400mg BD is first-line. Single dose is second-line. Partner notification is mandatory.
STI Treatment GuidelinesCDC (USA)20217-day Metronidazole 500mg BD for women. Single dose 2g for men.
European GuidelineIUSTI (Europe)2021Align with BASHH. Emphasises NAAT diagnosis.
WHO STI GuidelinesWHO (Global)2021Syndromic management often used in low-resource settings.

Landmark Trials & Evidence

1. Seven-Day vs Single-Dose Metronidazole (Kissinger et al., 2018)

  • Study Type: Multicentre, open-label, RCT.
  • Population: Women with Trichomoniasis (n=623).
  • Intervention: Metronidazole 500mg BD x 7 days vs 2g Single Dose.
  • Outcome: Treatment failure at 4 weeks.
  • Results:
    • 7-day Group Failure: 10.6%
    • Single Dose Group Failure: 19.7%
    • Relative Risk: Single dose failure risk RR = 1.87.
  • Conclusion: 7-day course is significantly superior.
  • Clinical Impact: Changed CDC and BASHH guidelines to prefer 7-day course for women.
  • PMID: 30281989 (Link)

2. Treating Trichomoniasis in HIV (Kissinger et al., 2015)

  • Study Type: RCT.
  • Result: Treating T. vaginalis in HIV-positive women reduces genital HIV RNA shedding.
  • Implication: Treatment functions as "Treatment as Prevention" for HIV.
  • PMID: 26242185

3. Preterm Birth and Metronidazole (Klebanoff et al., 2001)

  • Study Type: Large RCT.
  • Finding: Treating asymptomatic Trichomoniasis in pregnancy did NOT reduce preterm birth (and might have slightly increased it in some subgroups).
  • Nuance: This refers to asymptomatic screening. Symptomatic women must always be treated.
  • PMID: 11516431

4. Partner Treatment Efficacy (Seña et al., 2007)

  • Finding: Partner notification and treatment reduces recurrence rates by >75%.
  • Implication: Treat the partner or the patient will return.

5. NAAT vs Culture vs Wet Mount (Hobbs et al., 2013)

  • Study: Comparison of diagnostic methods.
  • Sensitivity Data:
    • Wet Mount: 51%
    • Culture: 75%
    • Aptima TV (NAAT): 98%
  • Conclusion: Microscopy misses half of all cases. NAAT is essential.
  • PMID: 23392437

Guideline Discordance Areas

IssueBASHH (UK)CDC (USA)Explanation
Treatment for Men7-day course preferredSingle dose 2g preferredCDC prioritises adherence in men; BASHH prioritises efficacy.
Screening in PregnancySymptomatic onlySymptomatic onlyBoth agree asymptomatic screening not routinely recommended.
Follow-UpNo TOC if asymptomaticRescreen at 3 monthsCDC aggressive on re-screening due to high reinfection rates in US.

Evolving Evidence: Resistance

  • Prevalence: Currently low (Less than 5%) but rising.
  • Mechanism: Downregulation of biological activation of metronidazole.
  • Testing: Only at specialist centres (e.g., CDC, reference labs).
  • New Drugs: Secnidazole (single dose 2g) FDA approved (2017) – similar to metronidazole but longer half-life.

11. Patient/Layperson Explanation

What is Trichomoniasis?

Trichomoniasis (or "Trich") is a very common sexually transmitted infection (STI). It is caused by a tiny parasite (not a bacteria or virus).

  • It is very common: Millions of people get it every year.
  • It is easily treated: Antibiotics usually cure it completely.
  • It is not dangerous (mostly): But it can cause problems in pregnancy if untreated.

Signs and Symptoms

In Women: Most women (about 7 in 10) have symptoms:

  • Discharge: It might be yellow or green, frothy, and have a strong, fishy smell.
  • Itching: Soreness or severe itching around the vagina.
  • Pain: Discomfort when passing urine or during sex.

In Men: Most men (9 in 10) have NO symptoms. They carry the parasite without knowing.

  • Occasionally: Mild discharge or irritation inside the penis.
  • Risk: Because they feel fine, they pass it on unknowingly.

How is it Treated?

The treatment is an antibiotic called Metronidazole.

  • usually taken twice a day for 7 days.
  • Sometimes given as a single large dose.

⚠️ IMPORTANT: The "No Alcohol" Rule

You MUST NOT drink any alcohol while taking these tablets, and for 48 hours (2 days) after finishing the course.

If you drink Alcohol...What will happen?
Even a small amountSevere reaction
ReactionViolent vomiting, Flushing (face goes red), Thumping headache, Racing heart
DurationCan aid serious illness
SafetyJust wait 48 hours to be safe!

Partner Notification: The Hard Part

You must tell your sexual partner(s). Even if they feel 100% fine.

  • If they are not treated, they will pass it straight back to you.
  • Then you will need to take the antibiotics again!

How to say it:

"I've just been diagnosed with an infection called Trichomoniasis. It's easily treated with tablets, but you need to get treated too, even if you have no symptoms. Please go to a clinic this week."

Myth Buster

MythFact
"He has no symptoms, so he's clean."FALSE. Men rarely have symptoms but still carry and spread it.
"I can wash it away."FALSE. Douching makes it worse by changing vaginal balance.
"I can catch it from a toilet seat."FALSE. The parasite dies quickly outside the body. It is from sex.
"One pill is enough."FALSE. The 7-day course is much better at destroying the parasite.
"I can drink one glass of wine."FALSE. Even mouthwash with alcohol can sometimes trigger the reaction!

Frequently Asked Questions (FAQs)

Q: Will it affect my fertility? A: Generally no. Unlike Chlamydia or Gonorrhoea, it rarely damages the tubes. However, treating it creates a healthier environment for conception.

Q: Can I have sex during treatment? A: No. You should wait until you AND your partner have finished the tablets, plus 7 days. This allows the medication to work and ensures you don't pass it back and forth.

Q: I'm pregnant. Is the baby safe? A: Untreated trichomoniasis is linked to having the baby too early (preterm birth). Treating it reduces the infection, although the link to outcomes is complex. The antibiotic metronidazole is generally considered safe in pregnancy.

Q: How did I get it? I haven't had sex in months. A: In some cases, the infection can be present for months or even years without causing major symptoms, then suddenly "flare up." So it doesn't always prove a partner has cheated recently.

When to Seek Help Urgently

Go back to your doctor if:

  • You vomit the tablets up (you might need a re-dose).
  • Symptoms don't go away after the course.
  • You develop severe lower tummy pain or fever (could be a deeper infection).

12. References

Primary Guidelines

  1. Sherrard J, et al. 2021 UK National Guideline on the Management of Trichomonas vaginalis. British Association for Sexual Health and HIV (BASHH). 2021. Available at: BASHH
  2. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. 4):1–187. DOI: 10.15585/mmwr.rr7004a1
  3. Tiplica GS, et al. 2021 European Guideline on the Management of Trichomonas vaginalis. International Union against Sexually Transmitted Infections (IUSTI). 2021.
  4. World Health Organization. Guidelines for the management of symptomatic sexually transmitted infections. Geneva: WHO; 2021. ISBN: 978-92-4-002416-8.

Key Evidence & Trials

  1. Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(11):1251-1259. PMID: 30281989
  2. Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev. 2003;(2):CD000218. PMID: 12804383
  3. Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307. PMID: 26242185
  4. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med. 2001;345(7):487-493. PMID: 11516431
  5. Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44(1):13-22. PMID: 17143809

Epidemiology & Pathogenesis

  1. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548-562P.
  2. Hirt RP, Sherrard J. Trichomonas vaginalis origins, molecular pathobiology and clinical considerations. Curr Opin Infect Dis. 2015;28(1):72-79.
  3. Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev. 2004;17(4):794-803.

Diagnostics

  1. Hobbs MM, Seña AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect. 2013;89(6):434-438.
  2. Van Der Pol B, et al. Performance of the Aptima Trichomonas vaginalis assay for detection of Trichomonas vaginalis in men and women. J Clin Microbiol. 2016;54(1):7-12.
  3. Nathan B, et al. Microscopy in the diagnosis of Trichomonas vaginalis. Int J STD AIDS. 2015;26(5):351-354.

Complications & HIV

  1. McClelland RS, Sangaré L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195(4):569-577.
  2. Mavedzenge SN, Van Der Pol B, Weiss HA. The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS. 2012;26(5):617-624. [Evidence review of co-infections]
  3. Silver BJ, Guy RJ, Kaldor JM, et al. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review. Sex Transm Dis. 2014;41(6):369-376.

Review Articles

  1. Sobel JD. Trichomoniasis: What's new? Expert Rev Anti Infect Ther. 2017;15(12):1113-1116.
  2. Muzny CA, et al. The clinical spectrum of Trichomonas vaginalis infection in men. Clin Infect Dis. 2014;58(2):299-300.
  3. Meites E, et al. A review of evidence-based care of symptomatic trichomoniasis. Clin Infect Dis. 2015;61(Suppl 8):S837-S848.

Glossary of Terms

TermDefinition
Amine OdourA "fishy" smell produced by amines (e.g., putrescine, cadaverine) when vaginal pH increases, often intensified by adding KOH (Whiff test).
AxostyleA rigid, microscopic rod-like structure running through the Trichomonas cell, involved in attachment to host cells.
Colpitis MacularisThe medical term for "strawberry cervix" – punctate hemorrhages on the cervix seen in Trichomoniasis.
DyspareuniaPain during or after sexual intercourse. Deep dyspareunia suggests pelvic involvement; superficial suggests vulvitis.
FlagellumA microscopic whip-like appendage that enables many protozoa and bacteria to swim. T. vaginalis has four anterior and one posterior flagella.
FomiteAn inanimate object (e.g., damp towel) that can theoretically transmit infection, though extremely rare for T. vaginalis.
HydrogenosomeA specialised organelle found in T. vaginalis (instead of mitochondria) that produces hydrogen and ATP anaerobically; the target site for metronidazole.
Incubation PeriodThe time from sexual exposure to the onset of symptoms, typically 4-28 days for Trichomoniasis.
MetronidazoleA nitroimidazole antibiotic used to treat anaerobic bacteria and protozoa. It requires reduction in the organism to become active.
NAATNucleic Acid Amplification Test. A diagnostic technique (like PCR) that amplifies minute amounts of DNA/RNA to detect pathogens. Gold standard for Trichomoniasis.
NitroimidazoleThe class of antibiotics to which metronidazole and tinidazole belong.
ProtozoanA diverse group of unicellular eukaryotic organisms. Trichomonas is a protozoan (not a bacteria, virus, or fungus).
ReservoirA host who carries the pathogen often without symptoms, maintaining the infection chain (Asymptomatic men are the key reservoir).
TrophozoiteThe active, feeding stage of a protozoan parasite. T. vaginalis exists only in this form (no cyst stage).
Undulating MembraneA fin-like extension of the cell membrane in Trichomonas that aids in motility ("wobbly" swimming).
UrethritisInflammation of the urethra, often caused by STIs like Trichomonas, causing dysuria and discharge.
Wet MountA microscopic examination of fresh vaginal discharge mixed with saline to visualize motile organisms.
Whiff TestA clinical test where potassium hydroxide (KOH) is added to vaginal discharge; a fishy odour indicates amines (Positive in BV and Trichomoniasis).

13. Examination Focus

High-Yield Facts for Exams

FactValueExam Importance
OrganismProtozoan (Flagellated)Critical – NOT bacteria/virus
Classic DischargeFrothy, Yellow-green, Malodorous"Frothy" is the key buzzword
Pathognomonic SignStrawberry cervix (Colpitis macularis)"Strawberry" = Trichomoniasis
DiagnosisNAAT (Gold Standard)Replaces culture
MicroscopyMotile protozoa ("Twitching")Classic wet mount finding
pH FindingMore than 4.5 (Alkaline)Same as BV
Whiff TestPositive (Amine/Fishy)Same as BV
First-Line TreatmentMetronidazole 400mg BD x 7 daysBetter than single dose
InteractionDisulfiram-like with Alcohol"Antabuse reaction"
Partner TreatmentMandatory (Even if asymptomatic)Public health critical
HIV LinkIncreases acquisition (1.5-2x)Important complication

"Buzzword Bingo"

BuzzwordDiagnosis/Association
"Frothy discharge"Trichomoniasis
"Yellow-green discharge"Trichomoniasis
"Strawberry cervix"Trichomoniasis
"Flagellated organism"Trichomoniasis
"Motile protozoa"Trichomoniasis
"Punctate cervical hemorrhages"Trichomoniasis
"Clue cells"Bacterial Vaginosis (NOT Trich)
"Pseudohyphae"Candida (NOT Trich)

Common Exam Questions

Question 1 (SBA): A 24-year-old woman presents with offensive vaginal discharge. Speculum examination reveals a "strawberry cervix" with punctate hemorrhages. The vaginal pH is 5.5. What is the most likely causative organism? A. Candida albicans B. Gardnerella vaginalis C. Trichomonas vaginalis D. Neisseria gonorrhoeae E. Chlamydia trachomatis Answer: C (Pathognomonic sign + pH >4.5)

Question 2 (SBA): A 30-year-old woman is prescribed metronidazole for trichomoniasis. What specific advice must be given regarding alcohol consumption? A. Avoid alcohol for 1 hour after taking B. Alcohol decreases the efficacy of the drug C. Avoid alcohol during treatment and for 48 hours after D. Alcohol causes sedation with this drug E. No specific advice needed Answer: C (Disulfiram-like reaction: Flushing, Vomiting)

Question 3 (SBA): Which of the following complications is most strongly associated with untreated trichomoniasis in pregnancy? A. Congenital malformations B. Preterm delivery and low birth weight C. Neonatal conjunctivitis D. Neonatal pneumonia E. Hydrops fetalis Answer: B (Preterm delivery risk increased 1.4-1.8x)

OSCE Station: STI Counselling

Scenario: "Sarah, 23, has just been diagnosed with Trichomoniasis via a swab taken 3 days ago. She is currently asymptomatic. Please explain the diagnosis, management plan, and partner notification requirements."

Mark Scheme:

DomainCompetencyMarks
IntroductionIntroduce self, check identity, check understanding2
DiagnosisExplain "Trichomoniasis" clearly (STI, Parasite)2
Reassurance"It is very common and easily treated"1
TreatmentAntibiotics (Metronidazole) 1 week course2
Safety NettingALCOHOL WARNING (Crucial fail point if missed)3
Side EffectsNausea, Metallic taste1
Partner NotificationExplain need to treat current partner3
Sexual AbstinenceNo sex until both treated + 7 days2
Follow-UpAdvise return if symptoms persist1
HIV TestingOffer HIV test (Standard of care)2
ClosingSummarise, check understanding, leaflet1
Total20

Viva Points

Candidate Opening Statement:

"Trichomoniasis is a sexually transmitted infection caused by the flagellated protozoan Trichomonas vaginalis. It has a global incidence of over 150 million cases annually. Clinically, it presents with vulvitis and a characteristic frothy yellow-green discharge, though men are often asymptomatic reservoirs. Management involves 7 days of metronidazole, strict alcohol avoidance, and simultaneous partner treatment to prevent reinfection."

Examiner: "Why is the 7-day course preferred over the single dose?"

Candidate: "Meta-analyses (Cochrane) show the 7-day course has significantly higher cure rates (>95% vs ~85%) and lower reinfection rates compared to the 2g single dose. It is the recommended first-line treatment in UK (BASHH) and US (CDC) guidelines."

Examiner: "What is the mechanism of the alcohol reaction?"

Candidate: "Metronidazole inhibits the enzyme aldehyde dehydrogenase. This causes an accumulation of acetaldehyde when alcohol is consumed, leading to the 'disulfiram-like' reaction of flushing, tachycardia, nausea, and vomiting."

Common Mistakes to Avoid

MistakeCorrection
❌ "It's bacteria"✅ It is a PROTOZOAN PARASITE
❌ "Treat only if symptoms"✅ Treat asymptomatic partners to stop spread
❌ "Can drink a little"✅ Zero alcohol tolerance advised
❌ "Single dose is best"✅ 7-day course is superior (Gold standard)
❌ "It's harmless"✅ Linked to HIV acquisition and preterm birth

Clinical Reasoning Scenarios

Scenario A: Recurrent Symptoms

  • Situation: Patient treated 3 weeks ago returns with same symptoms.
  • Reasoning:
    1. Adherence: Did she take the pills? (And avoid alcohol/vomiting?)
    2. Reinfection: Did partner get treated? Did they have sex too soon? (Most common)
    3. Resistance: Rare, but possible.
  • Action: Retreatment (often higher dose) + STRICT partner management.

Scenario B: Pregnancy

  • Situation: 10 weeks pregnant, symptomatic.
  • Reasoning: Metronidazole generally safe, but avoid high stat doses in 1st trimester.
  • Action: Treat with standard 5-7 day course. Symptomatic relief outweighs theoretical risks.

Dangerous Errors (Automatic Fail)

[!CAUTION] OSCE Fail Points: > 1. Failing to warn about Alcohol interaction (Patient safety). > 2. Failing to address Partner notification (Public health). > 3. Dismissing symptoms in Pregnancy (Fetal risk).


Last Reviewed: 2025-12-25 | MedVellum Editorial Team


Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.

Last updated: 2025-12-25

At a Glance

EvidenceHigh
Last Updated2025-12-25

Red Flags

  • Pregnancy (Risk of preterm labour)
  • Pelvic Inflammatory Disease (Co-infection risk)
  • HIV Co-infection
  • Treatment Failure

Clinical Pearls

  • **"Most Common Curable STI Worldwide"**: 156 million cases/year. Often underdiagnosed compared to Chlamydia.
  • **"Protozoan, NOT Bacteria"**: Trichomonas is a flagellated protozoan. It does not respond to penicillin or doxycycline. It needs nitroimidazoles.
  • **"Strawberry Cervix"**: Pathognomonic sign, But only seen in ~2% with naked eye. Requires colposcopy to see in 50%.
  • **"Frothy, Fishy, Yellow-Green"**: The classic triad description for exams. If you hear "Frothy", think Trich.
  • **"Men Carry, Women Suffer"**: Men are often asymptomatic reservoirs who reinfect their treated female partners.

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines